It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
We transform complex biological data into clear, actionable insights, accelerating target discovery, hit-to-lead and candidate selection through integrated expertise and collaborative, science-driven solutions.
Bioinformatics is crucial in modern drug discovery. We integrate cutting-edge bioinformatics with connected expertise across biology, chemistry, translational science, and computational sciences, ensuring insights are translated into actionable drug discovery strategies.
Our team works as an extension of yours, providing flexible, bespoke solutions that de-risk discovery and accelerate progress from early target identification through to clinical insight.
Our Bioinformatics team transforms vast, complex datasets into clear. By integrating and analyzing diverse datasets, we identify promising targets, interpret experimental results, and uncover findings that shape the direction of drug discovery projects.
Every therapeutic area is different, so our solutions are flexible and bespoke to your program. From early target identification to translational insights, we provide end-to-end support designed to de-risk discovery and accelerate progress. Our multidisciplinary approach, collaborative mindset, and proven track record make Sygnature Discovery a trusted partner for advancing innovative therapies efficiently and with scientific rigor.
Sygnature Discovery’s Digital Drug Discovery Ecosystem Our bioinformatics capabilities sit within a connected digital ecosystem spanning discovery, preclinical, clinical, and drug repurposing stages. This integration ensures insights are actionable at every step of development, enabling smarter decisions and faster outcomes.
key questions we help answer
We support both target-centric and disease-centric research programs, working closely with our collocated chemistry, biology, and DMPK teams to deliver integrated solutions that move your discovery program forward.
Our flexible workflows adapt to your needs, whether you’re working with transcriptomics, proteomics, or clinical metadata.
Our Bioinformatics Services
Our services combine industry gold- standard tools with proprietary innovations to deliver reliable, decision-enabling data.
Expression Analysis and DNA/RNA- Sequencing
We deliver high-quality transcriptomic insights using best-in-class technologies such as Qiagen IPA, a semi automated Open Targets tractability pipeline, and automated RNA-seq workflows. These capabilities enable precise expression profiling, variant calling, and functional characterization for target validation and biomarker discovery.
Leveraging the Latest Bioinformatic Databases
To ensure accuracy and confidence in every result, we integrate and cross reference data with trusted resources including Qiagen Knowledge Base, Human Protein Atlas (HPA), GTEx, and TCGA. This multi database approach strengthens biological interpretation and supports robust decision-making, even across diverse therapeutic areas.
Fragment-Based Drug Discovery
We employ physicochemical property filters, fingerprint clustering and diversity analysis to curate and enhance our proprietary fragment library, increasing its quality for fragment-based drug discovery.
Series Identifications for Clustering and Profiling
Computational chemistry aids in analyzing in vitro screening results for hit finding, identifying promising series for progression through clustering and profiling.
Why Choose Sygnature Discovery for Bioinformatics Support?
Our team brings extensive expertise and cutting-edge technology to every project, with members averaging more than 15 years of experience across academia, biotech, and pharma, contributing a deep reservoir of domain knowledge to every project.
Embedded within Sygnature’s multi-decade legacy of drug discovery, we ensure bioinformatics insights are scientifically rigorous and strategically aligned with real-world therapeutic development.
This unique blend of experience, infrastructure, and collocated integration empowers us to deliver insights that accelerate decision-making and drive success across projects and therapeutic areas.
Collaboration at the Heart of Bioinformatics
Our bioinformatics capabilities are seamlessly integrated with Sygnature Discovery’s preclinical and translational services, including computational chemistry, biomarker discovery, high-throughput screening (HTS) and more.
This collaborative, cross-functional approach enables us to provide comprehensive, one-stop solutions for drug discovery, grounded in robust, data-driven evidence.
Ting Qin, Sergio Ernesto Ruiz Hernandez, Jason Shiers, Matthew Crittall, Andrew Novak, Colin Sambrook Smith Abstract Within a growing drug discovery company, scientists acquire (either through in house…
Journal Papers
ChemistryComputer aided drug designInformaticsInventory Management
Andrzej T Slominski, Tae-Kang Kim, Radomir M Slominski, Yuwei Song, Shariq Qayyum, Wojciech Placha, Zorica Janjetovic, Konrad Kleszczyński, Venkatram Atigadda, Yuhua Song, Chander Raman, Cornelis J…
Journal Papers
Computer aided drug design
FAQs
We offer end-to-end support for target and biomarker identification, including transcriptomics (bulk, single-cell, spatial RNAseq) and proteomics analysis, functional characterization and network biology, and variant calling. Our team integrates multi-omics data to guide strategic decisions across the discovery pipeline.
Yes. We routinely work with client-provided data and systems, ensuring seamless integration while maintaining scientific rigor and data security. Sygnature Discovery operates under ISO/IEC 27001-certified information security management systems, which guarantees that all client data is handled with the highest standards of confidentiality, integrity, and availability.
We use gold-standard tools like Qiagen IPA and Open Targets, we cross -reference findings with trusted databases (GTEx, TCGA, and Human Protein Atlas). We apply our automated workflows and expert reviews ensuring high-quality, reproducible review and sort Banner 1/2/3 levels on all Sgy pages content entry and update insights.
We work across oncology, immunology, metabolic disease, neuroscience, and rare diseases. Our team tailors bioinformatics strategies to the biological context and clinical relevance of each project.
Yes. We use semi-automated, human-in-the-loop pipelines alongside curated databases to assess target tractability, expression profiles, genetic associations, and disease linkage – helping you focus on the most promising candidates.
All our workflows are modular and customizable. Whether you need a one-off analysis or a fully embedded solution, we adapt our pipelines to your scientific goals, timelines, and data formats.
Yes. We provide follow-up consultations, data review sessions, and collaborative interpretation to ensure findings are actionable and aligned with your next steps.
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Target Identification & Validation
Combining AI-driven insights, expert guidance, and rigorous lab validation to select and confirm targets for successful drug discovery.
Global chemistry expertise and tailored strategies combining medicinal, synthetic, and process capabilities advancing candidate-quality molecules with transparent collaboration.
Tailored bioscience solutions combining advanced technologies and collaborative expertise to design robust assays and accelerate confident drug discovery decisions.
